Drugs / ACT-451840
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02223871 | Jun → Jul 2014 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02186002 | Dec 2011 → Apr 2012 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-451840 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02223871 ↗ |
| Modality | Small molecule | “ACT-451840, a new chemical entity with antimalarial activity.” PMID 25421475 ↗ Nov 2014 |
| Route | Oral | “A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state.” NCT02186002 ↗ |